References Cited
1. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to
newborn screening for Duchenne muscular dystrophy. Ann Neurol.2012;71(3):304-313.
2. Nowak KJ, Davies KE. Duchenne muscular dystrophy and dystrophin:
pathogenesis and opportunities for treatment. EMBO Rep.2004;5(9):872-876.
3. Mendell J, Sahenk Z, Lehman K, et al. Assessment of Systemic Delivery
of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular
Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol.2020;Published online June 15, 2020. doi:10.1001/jamaneurol.2020.1484.
4. Nance ME, Duan D. Perspective on Adeno-Associated Virus Capsid
Modification for Duchenne Muscular Dystrophy Gene Therapy. Hum
Gene Ther. 2015;26(12):786-800.
5. Bostick B, Shin JH, Yue Y, Duan D. AAV-microdystrophin therapy
improves cardiac performance in aged female mdx mice. Mol Ther.2011;19(10):1826-1832.
6. Salva MZ, Himeda CL, Tai PW, et al. Design of tissue-specific
regulatory cassettes for high-level rAAV-mediated expression in skeletal
and cardiac muscle. Mol Ther. 2007;15(2):320-329.
7. Xu R, Jia Y, Zygmunt DA, Martin PT. rAAVrh74.MCK.GALGT2 Protects
against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.Mol Ther. 2019;27(3):636-649.
8. Forand A, Muchir A, Mougenot N, et al. Combined Treatment with
Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and
AAV-U7 Rescues the Severe DMD Phenotype in Mice. Mol Ther Methods
Clin Dev. 2020;17:695-708.
9. Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing
improves muscle function in a mouse model of Duchenne muscular
dystrophy. Science. 2016;351(6271):403-407.
10. Hakim CH, Wasala NB, Nelson CE, et al. AAV CRISPR editing rescues
cardiac and muscle function for 18 months in dystrophic mice. JCI
Insight. 2018;3(23).
11. Nelson CE, Wu Y, Gemberling MP, et al. Long-term evaluation of
AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat
Med. 2019;25(3):427-432.
12. Li A, Tanner M, Lee C, et al. AAV-CRISPR gene editing is negated by
pre-existing immunity to Cas9. Mol Ther. 2020;28(6):1432-1441.
13. LoMauro A, Romei M, Gandossini S, et al. Evolution of respiratory
function in Duchenne muscular dystrophy from childhood to adulthood.Eur Respir J. 2018;51(2).
14. Chiou M, Bach JR, Jethani L, Gallagher MF. Active lung volume
recruitment to preserve vital capacity in Duchenne muscular dystrophy.J Rehabil Med. 2017;49(1):49-53.
15. McDonald CM, Gordish-Dressman H, Henricson EK, et al. Longitudinal
pulmonary function testing outcome measures in Duchenne muscular
dystrophy: Long-term natural history with and without glucocorticoids.Neuromuscul Disord. 2018;28(11):897-909.
16. Mayer OH, Finkel RS, Rummey C, et al. Characterization of pulmonary
function in Duchenne Muscular Dystrophy. Pediatr Pulmonol.2015;50(5):487-494.
17. Gayraud J, Ramonatxo M, Rivier F, Humberclaude V, Petrof B, Matecki
S. Ventilatory parameters and maximal respiratory pressure changes with
age in Duchenne muscular dystrophy patients. Pediatr Pulmonol.2010;45(6):552-559.
18. Phillips MF, Quinlivan RC, Edwards RH, Calverley PM. Changes in
spirometry over time as a prognostic marker in patients with Duchenne
muscular dystrophy. Am J Respir Crit Care Med.2001;164(12):2191-2194.
19. Finder JD, Birnkrant D, Carl J, et al. Respiratory care of the
patient with Duchenne muscular dystrophy: ATS consensus statement.Am J Respir Crit Care Med. 2004;170(4):456-465.
20. Finder J, Mayer OH, Sheehan D, et al. Pulmonary Endpoints in
Duchenne Muscular Dystrophy. A Workshop Summary. Am J Respir Crit
Care Med. 2017;196(4):512-519.
21. Rideau Y, Jankowski LW, Grellet J. Respiratory function in the
muscular dystrophies. Muscle Nerve. 1981;4(2):155-164.
22. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of
Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health,
and orthopaedic management. Lancet Neurol. 2018;17(4):347-361.
23. Birnkrant DJ, Ashwath ML, Noritz GH, et al. Cardiac and pulmonary
function variability in Duchenne/Becker muscular dystrophy: an initial
report. J Child Neurol. 2010;25(9):1110-1115.
24. McKim DA, Road J, Avendano M, et al. Home mechanical ventilation: a
Canadian Thoracic Society clinical practice guideline. Can Respir
J. 2011;18(4):197-215.
25. Molgat-Seon Y, Hannan LM, Dominelli PB, et al. Lung volume
recruitment acutely increases respiratory system compliance in
individuals with severe respiratory muscle weakness. ERJ Open
Res. 2017;3(1).
26. McKim DA, Katz SL, Barrowman N, Ni A, LeBlanc C. Lung volume
recruitment slows pulmonary function decline in Duchenne muscular
dystrophy. Arch Phys Med Rehabil. 2012;93(7):1117-1122.
27. Connolly AM, Florence JM, Zaidman CM, et al. Clinical trial
readiness in non-ambulatory boys and men with duchenne muscular
dystrophy: MDA-DMD network follow-up. Muscle Nerve.2016;54(4):681-689.
28. Katz SL, Barrowman N, Monsour A, Su S, Hoey L, McKim D. Long-Term
Effects of Lung Volume Recruitment on Maximal Inspiratory Capacity and
Vital Capacity in Duchenne Muscular Dystrophy. Ann Am Thorac Soc.2016;13(2):217-222.
29. Rall S, Grimm T. Survival in Duchenne muscular dystrophy. Acta
Myol. 2012;31(2):117-120.
30. Passamano L, Taglia A, Palladino A, et al. Improvement of survival
in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients.Acta Myol. 2012;31(2):121-125.
31. Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dystrophy:
survival by cardio-respiratory interventions. Neuromuscul Disord.2011;21(1):47-51.
32. McKim DA, Griller N, LeBlanc C, Woolnough A, King J. Twenty-four
hour noninvasive ventilation in Duchenne muscular dystrophy: a safe
alternative to tracheostomy. Can Respir J. 2013;20(1):e5-9.
33. Toussaint M, Steens M, Wasteels G, Soudon P. Diurnal ventilation via
mouthpiece: survival in end-stage Duchenne patients. Eur Respir
J. 2006;28(3):549-555.
34. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap
improves survival and rate of pulmonary function decline in patients
with ALS. J Neurol Sci. 1999;164(1):82-88.
35. Toussaint M, Soudon P, Kinnear W. Effect of non-invasive ventilation
on respiratory muscle loading and endurance in patients with Duchenne
muscular dystrophy. Thorax. 2008;63(5):430-434.
36. Schonhofer B, Wallstein S, Wiese C, Kohler D. Noninvasive mechanical
ventilation improves endurance performance in patients with chronic
respiratory failure due to thoracic restriction. Chest.2001;119(5):1371-1378.
37. Nickol AH, Hart N, Hopkinson NS, Moxham J, Simonds A, Polkey MI.
Mechanisms of improvement of respiratory failure in patients with
restrictive thoracic disease treated with non-invasive ventilation.Thorax. 2005;60(9):754-760.
38. Gomez-Merino E, Bach JR. Duchenne muscular dystrophy: prolongation
of life by noninvasive ventilation and mechanically assisted coughing.Am J Phys Med Rehabil. 2002;81(6):411-415.
39. Stehling F, Bouikidis A, Schara U, Mellies U. Mechanical
insufflation/exsufflation improves vital capacity in neuromuscular
disorders. Chron Respir Dis. 2015;12(1):31-35.
40. Neve V, Cuisset JM, Edme JL, et al. Sniff nasal inspiratory pressure
in the longitudinal assessment of young Duchenne muscular dystrophy
children. Eur Respir J. 2013;42(3):671-680.
41. Mercuri E, Muntoni F, Osorio AN, et al. Safety and effectiveness of
ataluren: comparison of results from the STRIDE Registry and CINRG DMD
Natural History Study. J Comp Eff Res. 2020;9(5):341-360.
42. Jin JB, Carter JC, Sheehan DW, Birnkrant DJ. Cardiopulmonary
phenotypic discordance is common in Duchenne muscular dystrophy.Pediatr Pulmonol. 2019;54(2):186-193.
43. Magri F, Govoni A, D’Angelo MG, et al. Genotype and phenotype
characterization in a large dystrophinopathic cohort with extended
follow-up. J Neurol. 2011;258(9):1610-1623.
44. Roy B, Friesen WJ, Tomizawa Y, et al. Ataluren stimulates ribosomal
selection of near-cognate tRNAs to promote nonsense suppression.Proc Natl Acad Sci U S A. 2016;113(44):12508-12513.
45. Khan N, Eliopoulos H, Han L, et al. Eteplirsen Treatment Attenuates
Respiratory Decline in Ambulatory and Non-Ambulatory Patients with
Duchenne Muscular Dystrophy. J Neuromuscul Dis.2019;6(2):213-225.
46. Buyse GM, Goemans N, van den Hauwe M, Meier T. Effects of
glucocorticoids and idebenone on respiratory function in patients with
duchenne muscular dystrophy. Pediatr Pulmonol.2013;48(9):912-920.
47. Buyse GM, Voit T, Schara U, et al. Efficacy of idebenone on
respiratory function in patients with Duchenne muscular dystrophy not
using glucocorticoids (DELOS): a double-blind randomised
placebo-controlled phase 3 trial. Lancet.2015;385(9979):1748-1757.
48. Birnkrant DJ, Ararat E, Mhanna MJ. Cardiac phenotype determines
survival in Duchenne muscular dystrophy. Pediatr Pulmonol.2016;51(1):70-76.
49. Vincken WG, Elleker MG, Cosio MG. Flow-volume loop changes
reflecting respiratory muscle weakness in chronic neuromuscular
disorders. Am J Med. 1987;83(4):673-680.
50. Hahn A, Bach JR, Delaubier A, Renardel-Irani A, Guillou C, Rideau Y.
Clinical implications of maximal respiratory pressure determinations for
individuals with Duchenne muscular dystrophy. Arch Phys Med
Rehabil. 1997;78(1):1-6.
51. Nicot F, Hart N, Forin V, et al. Respiratory muscle testing: a
valuable tool for children with neuromuscular disorders. Am J
Respir Crit Care Med. 2006;174(1):67-74.
52. Inacio MC, Chen Y, Paxton EW, Namba RS, Kurtz SM, Cafri G.
Statistics in Brief: An Introduction to the Use of Propensity Scores.Clin Orthop Relat Res. 2015;473(8):2722-2726.
53. Kempf L, Goldsmith JC, Temple R. Challenges of developing and
conducting clinical trials in rare disorders. Am J Med Genet A.2018;176(4):773-783.